Get the Stockscreener App
48.93
1.26%
0.61
After Hours:
48.50
-0.43
-0.88%
Crispr Therapeutics Ag stock is traded at $48.93, with a volume of 1.52M.
It is up +1.26% in the last 24 hours and down -11.52% over the past month.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
See More
Previous Close:
$48.32
Open:
$48.6591
24h Volume:
1.52M
Relative Volume:
0.79
Market Cap:
$4.66B
Revenue:
$38.34M
Net Income/Loss:
$-488.30M
P/E Ratio:
-8.7687
EPS:
-5.5801
Net Cash Flow:
$-303.14M
1W Performance:
+6.65%
1M Performance:
-11.52%
6M Performance:
-13.55%
1Y Performance:
+13.00%
1-Day Range:
$47.39
$49.00
1-Week Range:
$46.27
$50.63
52-Week Range:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Name
Crispr Therapeutics Ag
Sector
Industry
Phone
(617) 315-4600
Address
BAARERSTRASSE 14, ZUG
Compare CRSP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
48.93 | 4.60B | 38.34M | -488.30M | -303.14M | -5.5801 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | JP Morgan | Overweight |
| Feb-14-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-12-25 | Upgrade | TD Cowen | Sell → Hold |
| Feb-03-25 | Initiated | H.C. Wainwright | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| Aug-02-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-28-24 | Resumed | Guggenheim | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-11-23 | Downgrade | TD Cowen | Market Perform → Underperform |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-27-23 | Initiated | Mizuho | Buy |
| Aug-17-23 | Upgrade | Citigroup | Neutral → Buy |
| May-30-23 | Initiated | William Blair | Outperform |
| Apr-13-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Mar-07-23 | Initiated | Robert W. Baird | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Aug-09-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-23-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Upgrade | Citigroup | Sell → Neutral |
| Apr-21-21 | Upgrade | Jefferies | Hold → Buy |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-10-20 | Reiterated | Chardan Capital Markets | Buy |
| Dec-10-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-10-20 | Reiterated | Needham | Buy |
| Dec-07-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Jul-28-20 | Reiterated | Needham | Buy |
| Jul-14-20 | Initiated | SunTrust | Buy |
| Jun-15-20 | Reiterated | Canaccord Genuity | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-03-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-19-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-12-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-01-19 | Initiated | Jefferies | Buy |
| Jul-26-19 | Initiated | Canaccord Genuity | Buy |
| Jun-10-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-14-19 | Initiated | William Blair | Mkt Perform |
| Jan-28-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-22-19 | Downgrade | Citigroup | Neutral → Sell |
View All
Crispr Therapeutics Ag Stock (CRSP) Latest News
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Lags Revenue Estimates - Bitget
CRISPR Therapeutics (NASDAQ:CRSP) Announces Quarterly Earnings Results - MarketBeat
Crispr Therapeutics earnings missed by $0.20, revenue fell short of estimates - Investing.com
Crispr Therapeutics (CRSP) Reports Lower-Than-Expected Q4 Revenue - GuruFocus
CRISPR Therapeutics AG SEC 10-K Report - TradingView
Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q4 Revenue $864,000 - marketscreener.com
CRISPR Therapeutics Earnings Report: Q4 Overview - Benzinga
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire
CRISPR Therapeutics AG (CRSP) Stock Analysis: Unveiling A 69.80% Potential Upside - DirectorsTalk Interviews
Guidance Update: Is CRISPR Therapeutics AG backed by strong institutional buyingGlobal Markets & Daily Chart Pattern Signals - baoquankhu1.vn
Aug PreEarnings: Is CRISPR Therapeutics AG backed by strong institutional buyingCEO Change & Capital Protection Trading Alerts - baoquankhu1.vn
Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million - Yahoo Finance
Gene Editing Market Growth in Future Scope 2026-2033| CRISPR - openPR.com
Top CRISPR Companies for 2026 and How to Invest - The Motley Fool
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
CRISPR Therapeutics AG $CRSP Shares Bought by IQ EQ FUND MANAGEMENT IRELAND Ltd - MarketBeat
The Best Biotech Stocks to Buy - Morningstar
Citizens Maintains Outperform Rating On CRISPR Therapeutics (CRSP) Citing Undervalued Pipeline - Finviz
CRISPR Therapeutics AG (CRSP) Stock Analysis: Navigating The 64% Potential Upside - DirectorsTalk Interviews
CRISPR Therapeutics AG (CRSP) expected to beat earnings estimates: Should you buy? - MSN
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy? - Finviz
CRISPR Therapeutics (CRSP) Price Target Increased by 14.61% to 82.91 - Nasdaq
CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock? - TradingView
Pathway Capital Management LP Takes Position in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics (CRSP) to Release Quarterly Earnings on Tuesday - MarketBeat
Does CRISPR Therapeutics (CRSP) Pipeline Expansion And ARK’s Buying Redefine Its Long‑Term Narrative? - simplywall.st
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
Layoff Watch: Will CRISPR Therapeutics AG benefit from government policyQuarterly Trade Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
Why (CRSP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
CRISPR Therapeutics Milestones And ARK Backing Contrast With Valuation Gap - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Rating of "Hold" from Brokerages - MarketBeat
ARK’s Bigger CRISPR Therapeutics Stake Underscores Gene Editing Pipeline Story - simplywall.st
CRISPR Therapeutics (CRSP) Jumps 9.6% on Biotech Rally - MSN
Will CRISPR Therapeutics AG stock gain from lower inflationJuly 2025 Setups & Daily Profit Focused Stock Screening - mfd.ru
CRSP: Citizens Analyst Lowers Price Target to $80 | CRSP Stock N - GuruFocus
CRISPR Therapeutics (NASDAQ:CRSP) Given New $80.00 Price Target at Citizens Jmp - MarketBeat
CRISPR Therapeutics stock price target lowered to $80 by Citizens - Investing.com Nigeria
CRISPR Therapeutics CEO Share Sale Tests Confidence In Gene Editing Story - Sahm
ARK Investment Acquires Significant Stake in Crispr Therapeutics (CRSP) - GuruFocus
Forget AI Stocks: This Biotech Could Cure What AI Can't Touch - Finviz
Forget AI Stocks: This Biotech Could Cure What AI Can't Touch - The Motley Fool
What Does the Market Think About CRISPR Therapeutics AG? - Benzinga
BofA is Bullish on CRISPR Therapeutics AG (CRSP) - Insider Monkey
Assessing CRISPR Therapeutics (CRSP) Valuation After Recent Share Price Movements - Sahm
Why is CRISPR Therapeutics AG stock going downJuly 2025 Spike Watch & High Accuracy Swing Entry Alerts - mfd.ru
Top Executive Makes Bold Move With Fresh Crispr Therapeutics AG Stock Buy - TipRanks
CRISPR Therapeutics (NASDAQ:CRSP) Insider Purchases $49,703.68 in Stock - MarketBeat
CRISPR Therapeutics AG (CRSP) Stock Analysis: Unpacking the 52.71% Potential Upside for Investors - DirectorsTalk Interviews
Is CRISPR Therapeutics (CRSP) Still Attractive After A 67% Five Year Share Price Decline - Yahoo Finance
Assessing CRISPR Therapeutics’ Valuation As Recent Trading Puts CRSP Back In Focus - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why - sharewise.com
Crispr Therapeutics Ag Stock (CRSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):